Romania - romanès - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astrazeneca ab - suedia - metoprololum - compr. cu elib. prel. - 100mg - medicamente betablocante betablocante selective

Romania - romanès - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astrazeneca ab - suedia - metoprololum - compr. cu elib. prel. - 25mg - medicamente betablocante betablocante selective

Romania - romanès - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astrazeneca ab - suedia - metoprololum - compr. cu elib. prel. - 50mg - medicamente betablocante betablocante selective

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 190mg;   - modified release tablet - 190 mg - active: metoprolol succinate 190mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose light liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 47.5mg;   - modified release tablet - 47.5 mg - active: metoprolol succinate 47.5mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose light liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 95mg;   - modified release tablet - 95 mg - active: metoprolol succinate 95mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose light liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 23.75mg;   - modified release tablet - 23.75 mg - active: metoprolol succinate 23.75mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol tartrate 1 mg/ml;   - solution for injection - 1 mg/ml - active: metoprolol tartrate 1 mg/ml   excipient: sodium chloride water for injection - betaloc iv is indicated for the following indications: · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · suspected or definite myocardial infarction.

Malàisia - anglès - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

astrazeneca sdn. bhd. - metoprolol tartrate -

Estònia - estonià - Ravimiamet

recordati ireland limited - metoprolool - toimeainet prolongeeritult vabastav tablett - 50mg 100tk; 50mg 30tk; 50mg 28tk; 50mg 98tk